ConductScience.org, home

Paper30108856

Assessing the performance of docking scoring function, FEP, MM-GBSA, and QM/MM-GBSA approaches on a series of PLK1 inhibitors.

Pu C and 3 others. Medchemcomm, 2017. Cited by 29 papers, by iCite.

Cite this record

ConductScience Library. Assessing the performance of docking scoring function, FEP, MM-GBSA, and QM/MM-GBSA approaches on a series of PLK1 inhibitors. Papers, record 30108856. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30108856

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Assessing the performance of docking scoring function, FEP, MM-GBSA, and QM/MM-GBSA approaches on a series of PLK1 inhibitors.
PubMed
Journal
Medchemcomm
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
29
iCite
Relative citation ratio, by iCite
1.34
iCite
Revised in PubMed
2020-10-01
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pu CChunlanhttps://orcid.org/0000-0003-4892-1979
2Yan GGuoyi
3Shi JJianyou
4Li RRui

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118280498Rescoring docking hit lists for model cavity sites: predictions and experimental testing.J Mol Biol2008https://conductscience.org/library/papers/18280498PubMed
215766665ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.Cancer Cell2005https://conductscience.org/library/papers/15766665PubMed
321545145Use of a QM/MM-based FEP method to evaluate the anomalous hydration behavior of simple alkyl amines and amides: application to the design of FBPase inhibitors for the treatment of type-2 diabetes.J Am Chem Soc2011https://conductscience.org/library/papers/21545145PubMed
423789789Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models.J Phys Chem B2013https://conductscience.org/library/papers/23789789PubMed
515350223Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells.Mol Cell2004https://conductscience.org/library/papers/15350223PubMed
612488480Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells.J Natl Cancer Inst2002https://conductscience.org/library/papers/12488480PubMed
715640844Polo-like kinases (Plks) and cancer.Oncogene2005https://conductscience.org/library/papers/15640844PubMed
88991084Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes.J Cell Biol1996https://conductscience.org/library/papers/8991084PubMed
99126849Development and validation of a genetic algorithm for flexible docking.J Mol Biol1997https://conductscience.org/library/papers/9126849PubMed
1015785925Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications.Virchows Arch2005https://conductscience.org/library/papers/15785925PubMed
1127444142Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein-protein binding free energies and re-rank binding poses generated by protein-protein docking.Phys Chem Chem Phys2016https://conductscience.org/library/papers/27444142PubMed
1224683369Computing Clinically Relevant Binding Free Energies of HIV-1 Protease Inhibitors.J Chem Theory Comput2014https://conductscience.org/library/papers/24683369PubMed
1315176053Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades.Prostate2004https://conductscience.org/library/papers/15176053PubMed
1422172702Identification of novel, potent and selective inhibitors of Polo-like kinase 1.Bioorg Med Chem Lett2012https://conductscience.org/library/papers/22172702PubMed
1528144341Computational methods in drug discovery.Beilstein J Org Chem2016https://conductscience.org/library/papers/28144341PubMed
1619125657Empirical scoring functions for advanced protein-ligand docking with PLANTS.J Chem Inf Model2009https://conductscience.org/library/papers/19125657PubMed
1726216222Comparison of radii sets, entropy, QM methods, and sampling on MM-PBSA, MM-GBSA, and QM/MM-GBSA ligand binding energies of F. tularensis enoyl-ACP reductase (FabI).J Comput Chem2015https://conductscience.org/library/papers/26216222PubMed
1826592101Improving the Prediction of Absolute Solvation Free Energies Using the Next Generation OPLS Force Field.J Chem Theory Comput2012https://conductscience.org/library/papers/26592101PubMed
1925205360Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring.Phys Chem Chem Phys2014https://conductscience.org/library/papers/25205360PubMed
2018929484Imidazo[5,1-f][1,2,4]triazin-2-amines as novel inhibitors of polo-like kinase 1.Bioorg Med Chem Lett2008https://conductscience.org/library/papers/18929484PubMed

See all 28 referencesDownload CSV of references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.

PMIDTitleJournalYearIn PapersSource
41774209Computer-aided drug design in acute myeloid leukemia: a comprehensive review of advances, challenges, and future prospect.J Comput Aided Mol Des2026https://conductscience.org/library/papers/41774209PubMed
40723870Phytocompounds in Precision Dermatology: COX-2 Inhibitors as a Therapeutic Target in Atopic-Prone Skin.Biomolecules2025https://conductscience.org/library/papers/40723870PubMed
39339280Novel Autotaxin Inhibitor ATX-1d Significantly Enhances Potency of Paclitaxel-An In Silico and In Vitro Study.Molecules2024https://conductscience.org/library/papers/39339280PubMed
38650742Bioactive compounds from Morchella esculenta as potential inhibitors of RNA-binding protein La in ovarian cancer: a molecular modeling and quantum mechanics approach.In Silico Pharmacol2024https://conductscience.org/library/papers/38650742PubMed
37529282Modelling peptide-protein complexes: docking, simulations and machine learning.QRB Discov2022https://conductscience.org/library/papers/37529282PubMed
37241849Binding and Dynamics Demonstrate the Destabilization of Ligand Binding for the S688Y Mutation in the NMDA Receptor GluN1 Subunit.Molecules2023https://conductscience.org/library/papers/37241849PubMed
36988562Structure Determination of Challenging Protein-Peptide Complexes Combining NMR Chemical Shift Data and Molecular Dynamics Simulations.J Chem Inf Model2023https://conductscience.org/library/papers/36988562PubMed
36615367Comprehensive Survey of Consensus Docking for High-Throughput Virtual Screening.Molecules2022https://conductscience.org/library/papers/36615367PubMed
35930206Modeling receptor flexibility in the structure-based design of KRASG12C inhibitors.J Comput Aided Mol Des2022https://conductscience.org/library/papers/35930206PubMed
35720345Computational Structure Prediction for Antibody-Antigen Complexes From Hydrogen-Deuterium Exchange Mass Spectrometry: Challenges and Outlook.Front Immunol2022https://conductscience.org/library/papers/35720345PubMed
35629327Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy.Life (Basel)2022https://conductscience.org/library/papers/35629327PubMed
35039800Molecular docking-based computational platform for high-throughput virtual screening.CCF Trans High Perform Comput2022https://conductscience.org/library/papers/35039800PubMed
32340232Application of MM-PBSA Methods in Virtual Screening.Molecules2020https://conductscience.org/library/papers/32340232PubMed
32201802graphDelta: MPNN Scoring Function for the Affinity Prediction of Protein-Ligand Complexes.ACS Omega2020https://conductscience.org/library/papers/32201802PubMed
31956784Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases.ACS Omega2020https://conductscience.org/library/papers/31956784PubMed
31487867Molecular Docking: Shifting Paradigms in Drug Discovery.Int J Mol Sci2019https://conductscience.org/library/papers/31487867PubMed
31355188Refinement and Rescoring of Virtual Screening Results.Front Chem2019https://conductscience.org/library/papers/31355188PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
PLK15347PubTator's text mininghttps://conductscience.org/library/genes/5347

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30108856

GET https://conductscience.org/api/papers/v1/30108856/references?page=2